A plant-based diet boosts after-meal burn, leads to weight loss and improves cardiometabolic risk factors in overweight individuals, according to the outcomes from a randomised control trial by researchers with the Physicians Committee for Responsible Medicine.
Thirty-day morbidity and mortality outcomes after bariatric and metabolic surgery (BMS) during the COVID-19 pandemic are comparable to pre-pandemic levels, according to the findings from the Global 30-day outcomes after bariatric surgery during the COVID-19 pandemic (GENEVA) study.
Japanese researchers have reported that obesity causes are linked to various factors in addition to the individual's current socioeconomic circumstances, including childhood experiences, particularly those of abuse.
The gut hormone FGF19, released a few hours after eating, turns off fat production by regulating gene expression in the liver, but this regulation is abnormal in obesity, researchers at the University of Illinois Urbana-Champaign report. The study, ‘Intestinal FGF15/19 physiologically repress hepatic lipogenesis in the late fed-state by activating SHP and DNMT3A’, published in Nature Communications, was led by molecular and integrative physiology professor Jongsook Kim Kemper and research scientist Young-Chae Kim.
Saniona has announced positive top-line results from the Phase 2 open-label extension study of Tesomet in patients with hypothalamic obesity (HO). Patients treated with Tesomet for nearly one year (24 week double-blind followed by 24 week open label extension) demonstrated statistically significant and clinically meaningful reductions in body weight and waist circumference, as well as improvements in glycaemic control. No clinically meaningful differences in heart rate or blood pressure were observed over the course of the trial.
